AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

As tariff tensions and stubbornly high inflation whipsaw US stocks, bullish Wall Street forecasters are urging investors to ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

We explore some of the top blue-chip dividend ETFs, excluding the popular names like the Schwab US Dividend ETF (SCHD) ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...

Transmucosal drugs are a category of medications designed to be absorbed through mucous membranes, such as those found in the mouth, nasal passages, or gastrointestinal tract. These drugs are ...